menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Vemurafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Kechow Pharma \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Kechow Pharma \/ Roche"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tunlametinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Kechow Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai Kechow Pharma

    Menu

    Shanghai Kechow Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shanghai Kechow Pharma

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KeChow Gets NMPA Approval for Tunlametinib as First Targeted Therapy for NRAS Melanoma

                            Details : HL-085 (tunlametinib) is a small molecule inhibitor of Mitogen-activated protein kinase. It is approved by NMPA for the treatment of NRAS Mutated Advanced Melanoma.

                            Brand Name : HL-085

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 18, 2024

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai Kechow Pharma

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vemurafenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Roche and KeChow Reach a Cooperation Agreement

                            Details : Under this collaboration, KeChow will promote Roche's Zelboraf® in China. Zelboraf® is an oral small molecule, selective BRAF inhibitor indicated for the treatment of patients with BRAF V600 mutation-positive advanced or inoperable melanoma.

                            Brand Name : Zelboraf

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 20, 2021

                            Lead Product(s) : Vemurafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth